Jpmorgan Chase & CO Maxcyte, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MXCT
# of Institutions
124Shares Held
65.6MCall Options Held
1KPut Options Held
2K-
Cadian Capital Management, LP New York, NY8.19MShares$28.3 Million1.63% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$28.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.78MShares$19.9 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$17.4 Million7.62% of portfolio
-
Morgan Stanley New York, NY4.82MShares$16.6 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $351M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...